KISIMA-02 vaccine-based immunotherapy for patients with mutated pancreatic cancer

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501854-12-00

Acronym

KISIMA-02

Enrollment

Registered

2023-06-06

Start date

Unknown

Completion date

Unknown

Last updated

2023-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026